Search

Your search keyword '"Grund, Johanna"' showing total 7 results
Start Over Author "Grund, Johanna"
7 results on '"Grund, Johanna"'

1. Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma.

Author

Müller‐Meinhard, Berit, Seifert, Nicole, Grund, Johanna, Reinke, Sarah, Yalcin, Fatih, Kaul, Helen, Borchmann, Sven, von Tresckow, Bastian, Borchmann, Peter, Plütschow, Annette, Richter, Julia, Engert, Andreas, Altenbuchinger, Michael, Bröckelmann, Paul J., and Klapper, Wolfram

Published
2024
Full Text
View/download PDF

3. Low B‐cell content is associated with a CD73 ‐low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma

Author

Grund, Johanna, primary, Iben, Katharina, additional, Reinke, Sarah, additional, Bühnen, Ina, additional, Plütschow, Annette, additional, Müller‐Meinhard, Berit, additional, Garcia Marquez, Maria A., additional, Schlößer, Hans A., additional, von Tresckow, Bastian, additional, Kellermeier, Fabian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Bröckelmann, Paul J., additional, and Klapper, Wolfram, additional

Published
2023
Full Text
View/download PDF

6. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

Author

Gerhard‐Hartmann, Elena, primary, Goergen, Helen, additional, Bröckelmann, Paul J., additional, Mottok, Anja, additional, Steinmüller, Tabea, additional, Grund, Johanna, additional, Zamò, Alberto, additional, Ben‐Neriah, Susana, additional, Sasse, Stephanie, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Reinke, Sarah, additional, Engert, Andreas, additional, Veldman, Johanna, additional, Diepstra, Arjan, additional, Klapper, Wolfram, additional, and Rosenwald, Andreas, additional

Published
2021
Full Text
View/download PDF

7. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Author

Gerhard‐Hartmann, Elena, Goergen, Helen, Bröckelmann, Paul J., Mottok, Anja, Steinmüller, Tabea, Grund, Johanna, Zamò, Alberto, Ben‐Neriah, Susana, Sasse, Stephanie, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna, Diepstra, Arjan, Klapper, Wolfram, and Rosenwald, Andreas

Subjects
PROGRAMMED death-ligand 1, HODGKIN'S disease, MANTLE cell lymphoma, MAJOR histocompatibility complex
Abstract

Summary: High programmed cell death 1 ligand 1 (PD‐L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin‐ and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti‐PD‐1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD‐L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti‐PD‐1‐based first‐line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced‐stage or r/r cHL. All but two cases (97%) showed PD‐L1 expression by the tumour cells in variable amounts. While MHC‐I was rarely expressed in >50% of HRSC, MHC‐II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD‐L1 and MHC‐I/II expression on early response to the highly effective anti‐PD‐1‐based NIVAHL first‐line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti‐PD‐1 first‐line cHL treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results